Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $162.00 at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) had its target price increased by Needham & Company LLC from $150.00 to $162.00 in a research note published on Friday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

SRPT has been the subject of several other reports. Cantor Fitzgerald reduced their target price on Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating for the company in a report on Friday, June 24th. The Goldman Sachs Group reduced their target price on Sarepta Therapeutics from $181.00 to $155.00 and set a buy rating for the company in a report on Tuesday, May 24th. StockNews.com lowered Sarepta Therapeutics from a buy rating to a hold rating in a report on Saturday, May 21st. Credit Suisse Group reduced their price objective on Sarepta Therapeutics from $95.00 to $90.00 and set a neutral rating for the company in a report on Friday, June 24th. Finally, Morgan Stanley reduced their price objective on Sarepta Therapeutics from $77.00 to $74.00 and set an equal weight rating for the company in a report on Thursday, May 19th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $120.25.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $92.95 on Friday. The company has a market cap of $8.13 billion, a PE ratio of -21.92 and a beta of 1.22. Sarepta Therapeutics has a 52 week low of $61.28 and a 52 week high of $101.24. The business has a 50 day moving average price of $75.54 and a 200-day moving average price of $75.66. The company has a quick ratio of 5.13, a current ratio of 5.56 and a debt-to-equity ratio of 1.28.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biotechnology company reported ($1.20) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.15. The firm had revenue of $210.83 million during the quarter, compared to the consensus estimate of $208.25 million. Sarepta Therapeutics had a negative return on equity of 52.06% and a negative net margin of 46.56%. The company’s quarterly revenue was up 43.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.10) earnings per share. Equities analysts anticipate that Sarepta Therapeutics will post -4.54 earnings per share for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Emerald Advisers LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $281,000. Dupont Capital Management Corp purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $333,000. Exchange Traded Concepts LLC lifted its stake in Sarepta Therapeutics by 191.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 633 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 416 shares in the last quarter. Lehman & Derafelo Financial Resources LLC purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $385,000. Finally, Amalgamated Bank lifted its stake in Sarepta Therapeutics by 10.3% in the 1st quarter. Amalgamated Bank now owns 19,175 shares of the biotechnology company’s stock worth $1,498,000 after purchasing an additional 1,793 shares in the last quarter. 81.43% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Further Reading

The Fly logo

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.